Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections. It is a first-in-class inhibitor targeting the endonuclease activity of the virus polymerase acidic (PA) protein. Clinical trial data revealed that PA amino acid substitutions at residue 38 (I38T/F/M) reduced BXM potency and caused virus...

中文翻译：

---

Baloxavir敏感性降低的甲型和乙型流感病毒在体外的适应性降低，但保留了雪貂的可传播性[微生物学]

Baloxavir marboxil（BXM）于2018年被批准用于治疗甲型和乙型流感病毒感染。它是针对病毒聚合酶酸性（PA）蛋白的核酸内切酶活性的一流抑制剂。临床试验数据显示，残基38（I38T / F / M）上的PA氨基酸取代降低了BXM的效力并引起了病毒。